Home
/

What is a Bilirubin-to-Albumin Ratio Blood Test?

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Quick answer:

The Bilirubin-to-Albumin Ratio (BAR) compares bilirubin load against albumin-binding capacity, integrating liver excretory function, synthetic capacity, and red cell turnover into one metric that shows how close the system is to being overwhelmed. In newborns, elevated BAR is associated with greater risk of unbound bilirubin crossing the blood-brain barrier; in adults with liver disease, sepsis, or heart failure, persistently high BAR is associated with higher mortality risk.

Read more →
Table of contents

Bilirubin load against the body's main carrier protein

The Bilirubin-to-Albumin Ratio (BAR) is a calculated number that compares the amount of the yellow pigment made when red blood cells are broken down (bilirubin) with the amount of the main carrier protein in blood (albumin). Bilirubin is produced from heme in the spleen and other tissues, released into the bloodstream in an unconjugated form, and carried to the liver while bound to albumin. Albumin itself is made by the liver and circulates widely, transporting many substances and helping keep fluid in the vessels.

BAR highlights the balance between how much bilirubin the body needs to transport and how much albumin is available to carry it. Because bilirubin travels safely when bound to albumin, this ratio reflects the bloodstream's buffering capacity against unbound ("free") bilirubin and its movement into tissues. It integrates several processes at once: red cell turnover (heme catabolism), liver uptake and processing of bilirubin (conjugation and excretion), and liver protein production (albumin synthesis). In short, BAR summarizes the interplay between bilirubin load and albumin-based transport in a single, intuitive measure.

Why a ratio adds context that total bilirubin can't

The bilirubin-to-albumin ratio (BAR) captures the balance between how much bilirubin your body produces and clears, and how much albumin is available to bind and safely transport it. It links red blood cell turnover, liver detoxification, and protein/nutritional status to downstream effects on the brain, kidneys, and circulation. There isn't a single universal reference range; in general, a low, stable BAR is expected in healthy adults, and the within reference ranges zone tends to be toward the low end.

It integrates bilirubin load with binding capacity and liver function. At a systems level it reflects hepatic excretory and synthetic capacity, protein status, and inflammation, which influence energy metabolism, detoxification, drug binding, and—especially in newborns—neuroprotection.

Low, in-range, and high BAR patterns

When the ratio is low, it usually reflects efficient hepatic uptake and excretion of bilirubin with ample albumin production. People typically feel well, with no jaundice or fluid retention. In newborns, a low BAR is reassuring for low risk of bilirubin-related neurotoxicity. During pregnancy, albumin naturally runs lower, so very low ratios are less common even when liver function is normal.

Low values usually reflect low bilirubin production and/or ample albumin. This points to efficient hepatic uptake and conjugation, limited hemolysis, and good protein status. System-level effects are generally benign. Men often have slightly higher bilirubin than women, so very low ratios are more common in women.

Being in range suggests balanced heme turnover, intact liver processing and excretion, and sufficient albumin synthesis. This supports stable osmotic balance, transport of hormones and drugs, and controlled oxidative signaling. In most cohorts, optimal BAR tends to sit toward the low-to-mid portion of the reference interval.

When the ratio is high, either bilirubin is elevated, albumin is reduced, or both. This pattern appears with hepatocellular injury, cholestasis, hemolysis, systemic inflammation, or malnutrition. Symptoms can include jaundice, dark urine, pale stools, itching, and fatigue; low albumin can add leg swelling or ascites. In infants, a high BAR signals greater risk of bilirubin crossing the blood–brain barrier. In pregnancy, dilutional hypoalbuminemia can magnify the ratio, and liver complications can push it higher.

High values usually reflect increased bilirubin (from hepatocellular injury, cholestasis, or hemolysis) and/or reduced albumin from inflammation, liver synthetic impairment, or malnutrition. This combination signals strained hepatic capacity and lower binding reserve. In neonates, a high BAR correlates with higher risk of bilirubin neurotoxicity. During pregnancy, physiological hypoalbuminemia can raise BAR even when bilirubin is normal.

What shifts each side of the ratio

Albumin falls with acute illness and pregnancy and rises with dehydration; bilirubin rises with fasting, hemolysis, or Gilbert syndrome. Some drugs displace bilirubin from albumin. Sample hemolysis or light exposure can alter bilirubin measurement. Reference intervals differ by age and lab, and neonatal ranges are distinct from adult values.

Clearance capacity and binding reserve, integrated

BAR integrates liver clearance capacity, binding/transport reserve, and hemolysis into one metric. Tracked alongside ALT/AST, ALP/GGT, INR, platelet count, and kidney markers, it helps stage liver stress and forecast outcomes in liver disease, sepsis, and heart failure, where persistently high ratios track with higher risk.

FAQs

BAR testing uses total bilirubin and serum albumin from a blood sample to assess bilirubin clearance and protein synthesis in a single metric.

Testing BAR helps track liver burden and reserve, protein and inflammatory status via albumin, and overall recovery capacity, especially when other liver enzymes appear borderline or discordant.

Test periodically to establish a baseline and monitor trends, especially when changing medications, alcohol intake, training load, or nutrition that could affect liver function.

Hydration, systemic inflammation, nutrition, alcohol intake, medication effects, hemolysis, bile flow, and underlying liver conditions can shift bilirubin and/or albumin and therefore BAR.

BAR is derived from a standard blood draw. Follow the instructions provided with your test; some protocols advise avoiding heavy exercise or alcohol shortly beforehand.

Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.

We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.

References

  1. Iskander, I., Gamaleldin, R., El Houchi, S., El Shenawy, A., Seoud, I., El Gharbawi, N., Abou-Youssef, H., Aravkin, A., & Wennberg, R. P. (2014). Serum bilirubin and bilirubin/albumin ratio as predictors of bilirubin encephalopathy. Pediatrics, 134(5), e1330-e1339. https://doi.org/10.1542/peds.2013-1764
  2. Fevery, J. (2008). Bilirubin in clinical practice: A review. Liver International, 28(5), 592-605. https://doi.org/10.1111/j.1478-3231.2008.01716.x
  3. Fanali, G., di Masi, A., Trezza, V., Marino, M., Fasano, M., & Ascenzi, P. (2012). Human serum albumin: From bench to bedside. Molecular Aspects of Medicine, 33(3), 209-290. https://doi.org/10.1016/j.mam.2011.12.002
  4. Soeters, P. B., Wolfe, R. R., & Shenkin, A. (2019). Hypoalbuminemia: Pathogenesis and clinical significance. JPEN. Journal of Parenteral and Enteral Nutrition, 43(2), 181-193. https://doi.org/10.1002/jpen.1451
  5. Kwo, P. Y., Cohen, S. M., & Lim, J. K. (2017). ACG clinical guideline: Evaluation of abnormal liver chemistries. The American Journal of Gastroenterology, 112(1), 18-35. https://doi.org/10.1038/ajg.2016.517

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey